ALC Alcon
- 89.130
- +0.780+0.88%
- 89.125
- -0.005-0.01%
Alcon News
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to Its Board of Directors and Scientific Advisory Board
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D.,
Switzerland's Alcon Launches Middle East Headquarters in Saudi Arabia
Geneva, Switzerland-based Alcon (ALC.SW) formally opened its Middle East headquarters in Jeddah, Saudi Arabia, according to a Tuesday release. The Swiss company said its Jeddah headquarters allows the
Form 144 | Alcon(ALC.US) Officer Proposes to Sell 268.63K in Common Stocks
SEC FILLINGS DISCLOSED/ May 24, $Alcon(ALC.US)$ Officer Attias Laurent intends to sell 3,000 shares of its common stock on May 24, with a total market value of approximately $268.63K. Attias Laurent
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
UBS Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $100.56
UBS analyst Graham Doyle maintains $Alcon(ALC.US)$ with a buy rating, and adjusts the target price from $95.46 to $100.56.According to TipRanks data, the analyst has a success rate of 42.9% and a tota
Top Gap Ups and Downs on Wednesday: ADI, TJX, SCCO and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
UBS Lifts Alcon PT, Keeps Buy Recommendation
UBS on Wednesday increased its price target for eye care products company Alcon (ALC.SW) to 92.00 francs from 87.00 francs, with an unchanged buy rating.
UBS Sticks to Their Buy Rating for Alcon (ALC)
Express News | NYSE Order Imbalance 86068.0 Shares on Sell Side
MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio?
These large-cap stocks were the best performers in the last week. Are they in your portfolio?MicroStrategy Incorporated (NASDAQ:MSTR) shares increased 30.10% following a rise in the price of Bitcoin.M
Form 144 | Alcon(ALC.US) Officer Proposes to Sell 198.5K in Common Stocks
SEC FILLINGS DISCLOSED/ May 17, $Alcon(ALC.US)$ Officer Duplan Sergio intends to sell 2,250 shares of its common stock on May 17, with a total market value of approximately $198.5K. Duplan Sergio ha
Moody's Upgrades Alcon on Strong Financial Performance
Moody's on Friday upgraded Alcon's (ALC.SW) long-term issuer rating to Baa1 from Baa2, mainly driven by the Swiss eye care products company's continued strong financial performance. The rating agency
C-MER Eye Care Sells Stake in Israel-Based Belkin Vision to Alcon
A unit of C-MER Eye Care Holdings (HKG:3309) sold its equity interests in Belkin Vision, maker of the Eagle laser for glaucoma, to Swiss eye care giant Alcon Pharmaceuticals, according to a Thursday f
Hima Ophthalmology subsidiary has sold its shares in Belkin Vision Ltd., to Alcon
Hima Ophthalmology (03309) announced that Hong Kong (International) Eye Care Group Co., Ltd. (Hong Kong Ophthalmology), a wholly-owned subsidiary of the company, has sold it to Belkin Vision Ltd. (Sale Company) shares are vested in Alcon Pharmaceuticals Ltd (Alcon). Its book value as at 31 December 2023 was HK$23.3 million, and classified as a financial asset that includes other full income at fair value. The costs are as follows: the fixed cash cost at completion is approximately US$6.4 million; and possibly the cost does not exceed US$17 million,
Hima Ophthalmology (03309.HK) has sold shares in Belkin Vision Ltd., to Alcon
On May 16, GLONGHUI (03309.HK) announced that Hong Kong (International) Ophthalmology Group Co., Ltd., a wholly-owned subsidiary of the company, has sold its shares in Belkin Vision Ltd. (the selling company) to Alcon Pharmaceuticals Ltd (Alcon). Its book value as of 31 December 2023 was HK$23.3 million, and classified as a financial asset that includes other full income at fair values. The costs are as follows: the fixed cash cost at completion is approximately $6.4 million; and the likely cost is not more than $17.0 million
Kepler Capital Reaffirms Their Sell Rating on Alcon (ALC)
Contact Lens Maker Alcon's Has New Growth Avenues, Analyst Upgrades Stock
Oppenheimer has upgraded Alcon Inc (NYSE:ALC) following firm first-quarter earnings and several new drivers coming into view.The analyst sees a new opportunity in glaucoma with the announced acquisiti
Alcon Is Maintained at Overweight by Wells Fargo
Alcon Is Maintained at Overweight by Wells Fargo
Express News | Wells Fargo Maintains Overweight on Alcon, Raises Price Target to $94
Express News | Oppenheimer Upgrades Alcon to Outperform, Announces $103 Price Target
Analysis
Price Target
No Data
